{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T01:40:34Z","timestamp":1775526034705,"version":"3.50.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,16]],"date-time":"2020-11-16T00:00:00Z","timestamp":1605484800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,11,16]],"date-time":"2020-11-16T00:00:00Z","timestamp":1605484800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      FGF23 controls serum l,25(OH)\n                      <jats:sub>2<\/jats:sub>\n                      D\n                      <jats:sub>3<\/jats:sub>\n                      levels and phosphate homeostasis. This study evaluates the effects of ferritin on intact PTH, FGF23, and l,25(OH)\n                      <jats:sub>2<\/jats:sub>\n                      D\n                      <jats:sub>3<\/jats:sub>\n                      in patients with major thalassemia. It also evaluates FGF23 changes in patients with hypoparathyroidism to clarify the interaction between FGF23 and PTH in the absence of proper PTH functioning in human.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this case-control study, 25 major-beta thalassemia patients with hypoparathyroidism were age- and gender-matched with major-beta thalassemia patients having normal parathyroid function. Biochemical studies assessed the serum calcium, albumin, phosphorus, alkaline phosphatase, PTH, FGF23, 25(OH) D, 1,25(OH)2D3, ferritin, and the fractional excretion of phosphorous.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      FGF23 was higher in the patients with hypoparathyroidism than the controls (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.002). The fractional excretion of phosphorous was lower in patients with hypoparathyroidism, despite the high level of FGF23 (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.001). There was a correlation between serum 1,25(OH)2D3 and FGF23 with ferritin in the controls (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u2009&lt;\u20090.001and\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u2009&lt;\u20090.001, respectively).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The present study showed a strong positive correlation between serum ferritin and levels of FGF23 and 1,25(OH)2D3. We hypothesized that ferritin could have a stimulatory effect on the production of 1,25(OH)2D3. Moreover, a rise in FGF23 in patients with thalassemia, might be either associated with the stimulating effect of PTH and 1,25(OH)2D3, or directly related to the stimulating effect of ferritin.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12882-020-02101-3","type":"journal-article","created":{"date-parts":[[2020,11,16]],"date-time":"2020-11-16T05:06:22Z","timestamp":1605503182000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Association of vitamin D and FGF23 with serum ferritin in hypoparathyroid thalassemia: a case control study"],"prefix":"10.1186","volume":"21","author":[{"given":"Forough","family":"Saki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Azita","family":"Salehifar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seyed Reza","family":"Kassaee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2224-7250","authenticated-orcid":false,"given":"Gholamhossein Ranjbar","family":"Omrani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,11,16]]},"reference":[{"issue":"4","key":"2101_CR1","first-page":"435","volume":"88","author":"V De Sanctis","year":"2018","unstructured":"De Sanctis V, Soliman AT, Canatan D, Elsedfy H, Karimi M, Daar S, et al. An ICET-A survey on Hypoparathyroidism in patients with Thalassaemia major and Intermedia: a preliminary report. Acta Bio Medica Atenei Parmensis. 2018;88(4):435\u201344.","journal-title":"Acta Bio Medica Atenei Parmensis"},{"issue":"4","key":"2101_CR2","first-page":"260","volume":"63","author":"AU Kurtoglu","year":"2012","unstructured":"Kurtoglu AU, Kurtoglu E, Temizkan AK. Effect of iron overload on endocrinopathies in patients with beta-thalassaemia major and intermedia. Endokrynol Pol. 2012;63(4):260\u20133.","journal-title":"Endokrynol Pol"},{"issue":"2","key":"2101_CR3","doi-asserted-by":"publisher","first-page":"693","DOI":"10.18203\/2320-6012.ijrms20180322","volume":"6","author":"S Gombar","year":"2018","unstructured":"Gombar S, Parihar K, Choudhary M. Comparative study of serum ferritin and vitamin D in thalassemia patients with healthy controls. Int J Res Med Sci. 2018;6(2):693\u20135.","journal-title":"Int J Res Med Sci"},{"issue":"6","key":"2101_CR4","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1210\/jc.2015-3907","volume":"101","author":"ML Brandi","year":"2016","unstructured":"Brandi ML, Bilezikian JP, Shoback D, Bouillon R, Clarke BL, Thakker RV, et al. Management of hypoparathyroidism: summary statement and guidelines. J Clin Endocrinol Metabol. 2016;101(6):2273\u201383.","journal-title":"J Clin Endocrinol Metabol"},{"key":"2101_CR5","doi-asserted-by":"publisher","first-page":"172","DOI":"10.3389\/fendo.2016.00172","volume":"7","author":"EG Abate","year":"2017","unstructured":"Abate EG, Clarke BL. Review of hypoparathyroidism. Front Endocrinol. 2017;7:172.","journal-title":"Front Endocrinol"},{"key":"2101_CR6","doi-asserted-by":"publisher","first-page":"18632","DOI":"10.1074\/jbc.M116.744052","volume":"291","author":"WB Sneddon","year":"2016","unstructured":"Sneddon WB, Ruiz GW, Gallo LI, Xiao K, Zhang Q, Rbaibi Y, et al. Convergent signaling pathways regulate parathyroid hormone and fibroblast growth factor-23 action on NPT2A-mediated phosphate transport. J Biol Chem. 2016;291:18632\u201342 jbc. M116. 744052.","journal-title":"J Biol Chem"},{"issue":"4","key":"2101_CR7","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1172\/JCI200419081","volume":"113","author":"T Shimada","year":"2004","unstructured":"Shimada T, Kakitani M, Yamazaki Y, Hasegawa H, Takeuchi Y, Fujita T, et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest. 2004;113(4):561\u20138.","journal-title":"J Clin Invest"},{"issue":"31","key":"2101_CR8","doi-asserted-by":"publisher","first-page":"28265","DOI":"10.1074\/jbc.M202527200","volume":"277","author":"T Yamashita","year":"2002","unstructured":"Yamashita T, Konishi M, Miyake A, K-i I, Itoh N. Fibroblast growth factor (FGF)-23 inhibits renal phosphate reabsorption by activation of the mitogen-activated protein kinase pathway. J Biol Chem. 2002;277(31):28265\u201370.","journal-title":"J Biol Chem"},{"issue":"2","key":"2101_CR9","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1006\/bbrc.2000.3696","volume":"277","author":"T Yamashita","year":"2000","unstructured":"Yamashita T, Yoshioka M, Itoh N. Identification of a novel fibroblast growth factor, FGF23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. Biochem Biophys Res Commun. 2000;277(2):494\u20138.","journal-title":"Biochem Biophys Res Commun"},{"issue":"9","key":"2101_CR10","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1016\/j.yexcr.2012.02.027","volume":"318","author":"LD Quarles","year":"2012","unstructured":"Quarles LD. Role of FGF23 in vitamin D and phosphate metabolism: implications in chronic kidney disease. Exp Cell Res. 2012;318(9):1040\u20138.","journal-title":"Exp Cell Res"},{"issue":"8","key":"2101_CR11","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1002\/jbmr.401","volume":"26","author":"D Ranch","year":"2011","unstructured":"Ranch D, Zhang MY, Portale AA, Perwad F. Fibroblast growth factor 23 regulates renal 1, 25-dihydroxyvitamin D and phosphate metabolism via the MAP kinase signaling pathway in Hyp mice. J Bone Miner Res. 2011;26(8):1883\u201390.","journal-title":"J Bone Miner Res"},{"key":"2101_CR12","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.2215\/CJN.02680310","volume":"5","author":"D Pri\u00e9","year":"2010","unstructured":"Pri\u00e9 D, Friedlander G. Reciprocal control of 1, 25-dihydroxyvitamin D and FGF23 formation involving the FGF23\/Klotho system. Clin J Am Soc Nephrol. 2010;5:1717\u201322 CJN. 02680310.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5034","key":"2101_CR13","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1126\/science.1658941","volume":"254","author":"H Juppner","year":"1991","unstructured":"Juppner H, Abou-Samra A-B, Freeman M, Kong XF, Schipani E, Richards J, et al. AG protein-linked receptor for parathyroid hormone and parathyroid hormone-related peptide. Science. 1991;254(5034):1024\u20136.","journal-title":"Science."},{"issue":"2","key":"2101_CR14","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/S1534-5807(02)00218-6","volume":"3","author":"J Guo","year":"2002","unstructured":"Guo J, Chung U-I, Kondo H, Bringhurst FR, Kronenberg HM. The PTH\/PTHrP receptor can delay chondrocyte hypertrophy in vivo without activating phospholipase C. Dev Cell. 2002;3(2):183\u201394.","journal-title":"Dev Cell"},{"issue":"7","key":"2101_CR15","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1210\/jc.2008-2396","volume":"94","author":"BJ Schouten","year":"2009","unstructured":"Schouten BJ, Hunt PJ, Livesey JH, Frampton CM, Soule SG. FGF23 elevation and hypophosphatemia after intravenous iron polymaltose: a prospective study. J Clin Endocrinol Metabol. 2009;94(7):2332\u20137.","journal-title":"J Clin Endocrinol Metabol"},{"issue":"4","key":"2101_CR16","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/j.bone.2009.06.017","volume":"45","author":"Y Shimizu","year":"2009","unstructured":"Shimizu Y, Tada Y, Yamauchi M, Okamoto T, Suzuki H, Ito N, et al. Hypophosphatemia induced by intravenous administration of saccharated ferric oxide: another form of FGF23-related hypophosphatemia. Bone. 2009;45(4):814\u20136.","journal-title":"Bone."},{"issue":"8","key":"2101_CR17","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1002\/jbmr.1923","volume":"28","author":"M Wolf","year":"2013","unstructured":"Wolf M, Koch TA, Bregman DB. Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. J Bone Miner Res. 2013;28(8):1793\u2013803.","journal-title":"J Bone Miner Res"},{"issue":"3","key":"2101_CR18","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1007\/s10157-012-0725-0","volume":"17","author":"SM Deger","year":"2013","unstructured":"Deger SM, Erten Y, Pasaoglu OT, Derici UB, Reis KA, Onec K, et al. The effects of iron on FGF23-mediated Ca\u2013P metabolism in CKD patients. Clin Exp Nephrol. 2013;17(3):416\u201323.","journal-title":"Clin Exp Nephrol"},{"issue":"4","key":"2101_CR19","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/j.kint.2019.05.018","volume":"96","author":"B Czaya","year":"2019","unstructured":"Czaya B, Faul C. FGF23 and inflammation\u2014a vicious coalition in CKD. Kidney Int. 2019;96(4):813\u20135.","journal-title":"Kidney Int"},{"issue":"1","key":"2101_CR20","doi-asserted-by":"publisher","first-page":"F1","DOI":"10.1152\/ajprenal.00359.2016","volume":"312","author":"V David","year":"2017","unstructured":"David V, Francis C, Babitt JL. Ironing out the cross talk between FGF23 and inflammation. Am J Physiol-Renal Physiol. 2017;312(1):F1\u20138.","journal-title":"Am J Physiol-Renal Physiol"},{"issue":"4","key":"2101_CR21","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1159\/000485472","volume":"138","author":"C Wallquist","year":"2018","unstructured":"Wallquist C, Mansouri L, Norrb\u00e4ck M, Hylander B, Jacobson SH, Larsson TE, et al. Associations of fibroblast growth factor 23 with markers of inflammation and leukocyte transmigration in chronic kidney disease. Nephron. 2018;138(4):287\u201395.","journal-title":"Nephron."},{"issue":"7","key":"2101_CR22","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.2215\/CJN.13281211","volume":"7","author":"JM Mendoza","year":"2012","unstructured":"Mendoza JM, Isakova T, Ricardo AC, Xie H, Navaneethan SD, Anderson AH, et al. Fibroblast growth factor 23 and inflammation in CKD. Clin J Am Soc Nephrol. 2012;7(7):1155\u201362.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"14","key":"2101_CR23","doi-asserted-by":"publisher","first-page":"9795","DOI":"10.1074\/jbc.M113.527150","volume":"289","author":"LM Coe","year":"2014","unstructured":"Coe LM, Madathil SV, Casu C, Lanske B, Rivella S, Sitara D. FGF-23 is a negative regulator of prenatal and postnatal erythropoiesis. J Biol Chem. 2014;289(14):9795\u2013810.","journal-title":"J Biol Chem"},{"issue":"17","key":"2101_CR24","doi-asserted-by":"publisher","first-page":"4195","DOI":"10.3390\/ijms20174195","volume":"20","author":"B Czaya","year":"2019","unstructured":"Czaya B, Faul C. The role of fibroblast growth factor 23 in inflammation and anemia. Int J Mol Sci. 2019;20(17):4195.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2101_CR25","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.kint.2018.03.024","volume":"94","author":"Faul","year":"2018","unstructured":"Faul. FGF23 effects on the heart\u2014levels, time, source, and context matter. Kidney Int. 2018;94(1):7\u201311.","journal-title":"Kidney Int"},{"issue":"2","key":"2101_CR26","doi-asserted-by":"publisher","first-page":"143","DOI":"10.2174\/1570161115666170310092202","volume":"16","author":"G Cianciolo","year":"2018","unstructured":"Cianciolo G, Galassi A, Capelli I, Schillaci R, La Manna G, Cozzolino M. Klotho-FGF23, cardiovascular disease, and vascular calcification: black or white? Curr Vasc Pharmacol. 2018;16(2):143\u201356.","journal-title":"Curr Vasc Pharmacol"},{"issue":"12","key":"2101_CR27","doi-asserted-by":"publisher","first-page":"3409","DOI":"10.1007\/s00198-016-3719-z","volume":"27","author":"A Dede","year":"2016","unstructured":"Dede A, Trovas G, Chronopoulos E, Triantafyllopoulos I, Dontas I, Papaioannou N, et al. Thalassemia-associated osteoporosis: a systematic review on treatment and brief overview of the disease. Osteoporos Int. 2016;27(12):3409\u201325.","journal-title":"Osteoporos Int"},{"issue":"1","key":"2101_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12882-020-01826-5","volume":"21","author":"F Saki","year":"2020","unstructured":"Saki F, Kassaee SR, Salehifar A, Omrani GHR. Interaction between serum FGF-23 and PTH in renal phosphate excretion, a case-control study in hypoparathyroid patients. BMC Nephrol. 2020;21(1):1\u20136.","journal-title":"BMC Nephrol"},{"key":"2101_CR29","doi-asserted-by":"publisher","first-page":"15","DOI":"10.29328\/journal.hcem.1001003","volume":"1","author":"AG Pirin\u00e7\u00e7io\u011flu","year":"2017","unstructured":"Pirin\u00e7\u00e7io\u011flu AG, S\u00f6ker DG. Parathyroid functions in thalassemia major patients. Ann Clin Endocrinol Metab. 2017;1:15\u20139.","journal-title":"Ann Clin Endocrinol Metab"},{"issue":"4","key":"2101_CR30","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1002\/1529-0131(199904)42:4<799::AID-ANR25>3.0.CO;2-4","volume":"42","author":"Y Pawlotsky","year":"1999","unstructured":"Pawlotsky Y, Le Dantec P, Moirand R, Guggenbuhl P, Jouanolle AM, Catheline M, et al. Elevated parathyroid hormone 44\u201368 and osteoarticular changes in patients with genetic hemochromatosis. Arthr Rheumatism. 1999;42(4):799\u2013806.","journal-title":"Arthr Rheumatism"},{"issue":"2","key":"2101_CR31","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/S0950-3536(89)80017-4","volume":"2","author":"JM Gutteridge","year":"1989","unstructured":"Gutteridge JM, Halliwell B. 1 iron toxicity and oxygen radicals. Baillieres Clin Haematol. 1989;2(2):195\u2013256.","journal-title":"Baillieres Clin Haematol"},{"key":"2101_CR32","unstructured":"Modi AS, Poornima RT, DS JM. serum calcium and phosphate levels in patients with \u03b2-thalassemia major. Therapy. 2012;2(4):156."},{"issue":"6","key":"2101_CR33","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/j.bone.2005.11.018","volume":"38","author":"N Napoli","year":"2006","unstructured":"Napoli N, Carmina E, Bucchieri S, Sferrazza C, Rini G, Di Fede G. Low serum levels of 25-hydroxy vitamin D in adults affected by thalassemia major or intermedia. Bone. 2006;38(6):888\u201392.","journal-title":"Bone."},{"issue":"6","key":"2101_CR34","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1111\/j.1365-2141.2008.07135.x","volume":"141","author":"JC Wood","year":"2008","unstructured":"Wood JC, Claster S, Carson S, Menteer J, Hofstra T, Khanna R, et al. Vitamin D deficiency, cardiac iron and cardiac function in thalassaemia major. Br J Haematol. 2008;141(6):891\u20134.","journal-title":"Br J Haematol"},{"issue":"5","key":"2101_CR35","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1136\/adc.62.5.474","volume":"62","author":"P Dandona","year":"1987","unstructured":"Dandona P, Menon RK, Houlder S, Thomas M, Hoffbrand AV, Flynn DM. Serum 1, 25 dihydroxyvitamin D and osteocalcin concentrations in thalassaemia major. Arch Dis Child. 1987;62(5):474\u20137.","journal-title":"Arch Dis Child"},{"issue":"8","key":"2101_CR36","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1002\/cbf.2956","volume":"31","author":"N Charoenphandhu","year":"2013","unstructured":"Charoenphandhu N, Kraidith K, Teerapornpuntakit J, Thongchote K, Khuituan P, Svasti S, et al. 1, 25-Dihydroxyvitamin D3-induced intestinal calcium transport is impaired in \u03b2-globin knockout thalassemic mice. Cell Biochem Funct. 2013;31(8):685\u201391.","journal-title":"Cell Biochem Funct"},{"issue":"4","key":"2101_CR37","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1073\/pnas.71.4.1040","volume":"71","author":"Y Tanaka","year":"1974","unstructured":"Tanaka Y, DeLuca H. Role of 1, 25-dihydroxyvitamin D3 in maintaining serum phosphorus and curing rickets. Proc Natl Acad Sci. 1974;71(4):1040\u20134.","journal-title":"Proc Natl Acad Sci"},{"issue":"4","key":"2101_CR38","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1074\/jbc.M408903200","volume":"280","author":"H Saito","year":"2005","unstructured":"Saito H, Maeda A, Ohtomo S-i, Hirata M, Kusano K, Kato S, et al. Circulating FGF23 is regulated by 1\u03b1, 25-dihydroxyvitamin D3 and phosphorus in vivo. J Biol Chem. 2005;280(4):2543\u20139.","journal-title":"J Biol Chem"},{"issue":"6","key":"2101_CR39","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.bone.2005.03.002","volume":"36","author":"X Yu","year":"2005","unstructured":"Yu X, Sabbagh Y, Davis SI, Demay MB, White KE. Genetic dissection of phosphate-and vitamin D-mediated regulation of circulating Fgf23 concentrations. Bone. 2005;36(6):971\u20137.","journal-title":"Bone."},{"issue":"4","key":"2101_CR40","doi-asserted-by":"publisher","first-page":"F882","DOI":"10.1152\/ajprenal.00360.2010","volume":"299","author":"V Lavi-Moshayoff","year":"2010","unstructured":"Lavi-Moshayoff V, Wasserman G, Meir T, Silver J, Naveh-Many T. PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop. Am J Physiol-Renal Physiol. 2010;299(4):F882\u2013F9.","journal-title":"Am J Physiol-Renal Physiol"},{"issue":"5","key":"2101_CR41","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/ki.2011.107","volume":"80","author":"I L\u00f3pez","year":"2011","unstructured":"L\u00f3pez I, Rodr\u00edguez-Ortiz ME, Almad\u00e9n Y, Guerrero F, De Oca AM, Pineda C, et al. Direct and indirect effects of parathyroid hormone on circulating levels of fibroblast growth factor 23 in vivo. Kidney Int. 2011;80(5):475\u201382.","journal-title":"Kidney Int"},{"issue":"3","key":"2101_CR42","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1159\/000440968","volume":"131","author":"A Iguchi","year":"2015","unstructured":"Iguchi A, Kazama JJ, Yamamoto S, Yoshita K, Watanabe Y, Iino N, et al. Administration of ferric citrate hydrate decreases circulating FGF23 levels independently of serum phosphate levels in hemodialysis patients with iron deficiency. Nephron. 2015;131(3):161\u20136.","journal-title":"Nephron."},{"issue":"4","key":"2101_CR43","first-page":"324","volume":"10","author":"H Tangngam","year":"2018","unstructured":"Tangngam H, Mahachoklertwattana P, Poomthavorn P, Chuansumrit A, Sirachainan N, Chailurkit LO, et al. Under-recognized hypoparathyroidism in thalassemia. J Clin Res Pediatr Endocrinol. 2018;10(4):324.","journal-title":"J Clin Res Pediatr Endocrinol"},{"key":"2101_CR44","doi-asserted-by":"crossref","unstructured":"Clarke BL. FGF23 regulation of phosphorus homeostasis is dependent on PTH. Oxford University Press. 2011;152(11):4016\u201318.","DOI":"10.1210\/en.2011-1720"},{"issue":"3","key":"2101_CR45","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1507\/endocrj.K06-156","volume":"54","author":"H Yamashita","year":"2007","unstructured":"Yamashita H, Yamazaki Y, Hasegawa H, Yamashita T, Fukumoto S, Shigematsu T, et al. Fibroblast growth factor-23 (FGF23) in patients with transient hypoparathyroidism: its important role in serum phosphate regulation. Endocr J. 2007;54(3):465\u201370.","journal-title":"Endocr J"},{"key":"2101_CR46","volume-title":"Guidelines for the Management of Transfusion Dependent Thalassaemia (TDT)","author":"MD Cappellini","year":"2014","unstructured":"Cappellini MD, Cohen A, Porter J, et al. Guidelines for the Management of Transfusion Dependent Thalassaemia (TDT). 3rd ed. Nicosia: Thalassaemia International Federation; 2014. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK269382\/.","edition":"3"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-020-02101-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12882-020-02101-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-020-02101-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,16]],"date-time":"2020-11-16T05:17:09Z","timestamp":1605503829000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-020-02101-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,16]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2101"],"URL":"https:\/\/doi.org\/10.1186\/s12882-020-02101-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.17831\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.13092\/v1","asserted-by":"object"}]},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,16]]},"assertion":[{"value":"26 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Shiraz University of Medical Sciences local ethic committee and the Vice-chancellor of Research at SUMS approved this study with the code number of 1396-01-01-15805. All the patients signed a written informed consent form after a session of explaining the aim, method and goal of the study for each participant.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All the patients signed a written informed consent form for publication of any data from their results after a session of explaining the aim, method, and goal of the study for each participant.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Gholamhossein Ranjbar Omrani, Azita Salehifar, Seyed Reza Kassaee and Forough Saki declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"482"}}